|
|||
![]() |
|||
2016-04-12 15:15:42 CEST 2016-04-12 15:15:42 CEST REGULATED INFORMATION Biotie Therapies - Major shareholder announcementsDisclosure under Chapter 9, Section 5 of the Finnish Securities Markets ActBIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE April 12, 2016 at 4.15 p.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on April 11, 2016 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Versant Ventures V, LLC on behalf of itself and Versant Venture Capital V, L.P. According to the notification, the total number of Biotie shares owned directly or through financial instruments by Versant Ventures V, LLC and its funds has fallen below the threshold of 5 per cent on 11 April, 2016. Biotie's registered total number of shares and voting rights amounting to 1,089,608,083 has been used in the calculation of percentages for the announcement. Total positions of Versant Ventures V, LLC and its funds subject to the notification: +-----------------------+----------------+---------------------+---------------+ | |% of shares and |% of shares and |Total of both | | |voting rights |voting rights through|in % (A+B) | | |(total of A) |financial instruments| | | | |(total of B) | | +-----------------------+----------------+---------------------+---------------+ |Resulting situation on |Below 5 % |Below 5 % |Below 5 % | |the date on which | | | | |threshold was crossed | | | | |or reached | | | | +-----------------------+----------------+---------------------+---------------+ |Position of previous |5.39 |3.41 |8.80 | |notification (if | | | | |applicable) | | | | +-----------------------+----------------+---------------------+---------------+ Notified details of the resulting situation on the date on which the threshold was crossed or reached: A: Shares and voting rights +-----------------------+---------------------------+--------------------------+ |Class/type of shares |Number of shares and voting|% of shares and voting | |ISIN code (if possible)|rights |rights | | +---------+-----------------+---------+----------------+ | |Direct |Indirect |Direct |Indirect | | |(SMA 9:5)|(SMA 9:6 and 9:7)|(SMA 9:5)|(SMA 9:6 and | | | | | |9:7) | +-----------------------+---------+-----------------+---------+----------------+ |Shares |- |- |- |- | |(FI0009011571) | | | | | +-----------------------+---------+-----------------+---------+----------------+ |American Depositary |- |- |- |- | |Shares (ADS), each | | | | | |representing 80 Shares | | | | | |(FI0009011571) | | | | | +-----------------------+---------+-----------------+---------+----------------+ | | | | | | +-----------------------+---------+-----------------+---------+----------------+ |SUBTOTAL A | |Below 5 % | +-----------------------+---------------------------+--------------------------+ B: Financial instruments according to SMA 9:6a +-----------------+-------------+-------------+-------------+---------+--------+ |Type of financial|Expiration |Exercise/ |Physical or |Number of|% of | |instrument |date |Conversion |cash |shares |shares | | | |period |settlement |and |and | | | | | |voting |voting | | | | | |rights |rights | +-----------------+-------------+-------------+-------------+---------+--------+ |Warrants |Nov 1, 2020 |Nov 1, 2015 -|Physical |- |- | |entitling to | |Nov 1, 2020 |settlement | | | |subscribe for | | | | | | |Shares | | | | | | |(FI0009011571) | | | | | | +-----------------+-------------+-------------+-------------+---------+--------+ | | | | | | | +-----------------+-------------+-------------+-------------+---------+--------+ |SUBTOTAL B | |Below 5 | | | |% | +-------------+---------+--------+ Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity: +----------------------+------------------+----------------------+-------------+ |Name |% of shares and |% of shares and voting|Total of both| | |voting rights |rights through | | | | |financial instruments | | +----------------------+------------------+----------------------+-------------+ |Versant Ventures V, |Below 5 % |Below 5 % |Below 5 % | |LLC | | | | +----------------------+------------------+----------------------+-------------+ |Versant Venture |Below 5 % |Below 5 % |Below 5 % | |Capital V, L.P. | | | | +----------------------+------------------+----------------------+-------------+ |Versant Affiliates |Below 5 % |Below 5 % |Below 5 % | |Fund V, L.P. | | | | +----------------------+------------------+----------------------+-------------+ |Versant Ophthalmic |Below 5 % |Below 5 % |Below 5 % | |Affiliates Fund I, | | | | |L.P. | | | | +----------------------+------------------+----------------------+-------------+ |Versant Ventures V GP-|Below 5 % |Below 5 % |Below 5 % | |GP (Canada), Inc. | | | | +----------------------+------------------+----------------------+-------------+ |Versant Ventures V |Below 5 % |Below 5 % |Below 5 % | |(Canada), L.P. | | | | +----------------------+------------------+----------------------+-------------+ |Versant Venture |Below 5 % |Below 5 % |Below 5 % | |Capital V (Canada) LP | | | | +----------------------+------------------+----------------------+-------------+ According to the notification, Versant Ventures V, LLC is the sole general partner of (i) Versant Venture Capital V, L.P. (ii) Versant Affiliates Fund V, L.P. and (iii) Versant Ophthalmic Affiliates Fund I, L.P. and (iv) the sole shareholder of Versant Ventures V GP-GP (Canada), Inc. Versant Ventures V GP-GP (Canada), Inc. is the sole general partner of Versant Ventures V (Canada), L.P., which is the sole general partner of Versant Venture Capital V (Canada) LP. Neither Versant Ventures V, LLC nor any other entity under its control holds shares or financial instruments in the Company exceeding a notification threshold. Further, according to the notification, the investments of the Versant Venture III funds (controlled by Versant Ventures III, LLC) are under the Finnish Securities Markets Act not to be aggregated with the investments of the funds controlled by Versant Ventures V, LLC for the purposes of this notification. In Turku, April 12, 2016 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp. tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com DISTRIBUTION: Nasdaq Helsinki Ltd Main Media www.biotie.com [HUG#2002851] |
|||
|